The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome
Open accessAbstract
We recently described a subset of patients with a myeloproliferative variant of hypereosinophilic syndrome (MHES) characterized by elevated serum tryptase levels, increased atypical mast cells in the bone marrow, tissue fibrosis, and the presence of the fusion tyrosine kinase, FIP1L1-PDGFRα, which is a therapeutic target of imatinib mesylate. Seven patients with MHES were treated with imatinib mesylate (300-400 mg daily). Clinical improvement and resolution of eosinophilia was observed in all patients, although cardiac dysfunction, when present, was not altered by therapy. Reversal of bone marrow pathology, including increased cellularity, the presence of spindle-shaped mast cells, and myelofibrosis, was evident in all patients at 4 to 8 weeks following initiation of therapy. This was accompanied by a decrease in activated eosinophils and mast cells in the peripheral blood and bone marrow, respectively. Serum tryptase levels declined rapidly to normal levels in all patients and remained in the normal range throughout therapy. Molecular remission, with disappearance of detectable FIP1L1/PDGFRA (F/P) transcripts, was achieved in 5 of 6 patients tested. The lack of reversal of cardiac abnormalities and persistence of the F/P mutation in some patients suggests that early intervention with higher doses of imatinib mesylate may be desirable in the treatment of patients with MHES.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
FAUCI, A. S., HARLEY, J. B., ROBERTS, W. C., FERRANS, V. J., GRALNICK, H. R., & BJORNSON, B. H. (1982) · Annals of Internal Medicine · doi:10.7326/0003-4819-97-1-78 · Cited by 823
Cited by
Eosinophilic gastrointestinal disorders (EGID)
Rothenberg, M. E. (2004) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2003.10.047 · Cited by 923
Eosinophils: Biological Properties and Role in Health and Disease
HOGAN, S. P., ROSENBERG, H. F., MOQBEL, R., PHIPPS, S., FOSTER, P. S., LACY, P., KAY, A. B., & ROTHENBERG, M. E. (2008) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2008.02958.x · Cited by 834
Diagnostic Value of Tryptase in Anaphylaxis and Mastocytosis
Schwartz, L. B. (2006) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2006.05.010 · Cited by 477
Cardiovascular Manifestations of Hypereosinophilic Syndromes
Ogbogu, P. U., Rosing, D. R., & Horne, M. K. (2007) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2007.07.001 · Cited by 375
Approaches to the treatment of hypereosinophilic syndromes: A workshop summary report
Klion, A. D., Bochner, B. S., Gleich, G. J., Nutman, T. B., Rothenberg, M. E., Simon, H.-U., Wechsler, M. E., Weller, P. F., & the Hypereosinophilic Syndromes Working Group (2006) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2006.02.042 · Cited by 342
Self-citation
Metadata
- Authors
- Klion, A. D., Robyn, J., Akin, C., Noel, P., Brown, M., Law, M., Metcalfe, D. D., Dunbar, C., & Nutman, T. B.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2004-01-15
- Volume
- 103
- Issue
- 2
- Pages
- 473-478
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2019186253
- Cited by
- 240
- References
- 1
- FWCI
- 11.89
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. https://app.cochat.ai/papers/10.1182/blood-2003-08-2798
- The paper
- Klion, A. D., Robyn, J., Akin, C., Noel, P., Brown, M., Law, M., Metcalfe, D. D., Dunbar, C., & Nutman, T. B. (2004). Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood. https://doi.org/10.1182/blood-2003-08-2798
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.